

VIA EFS

Date of Deposit: June 8, 2009

Attorney Docket No. 25681-501 UTIL

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS :	Dotan, et al.	CONFIRMATION NO.:	7868
U.S. PATENT NO.:	7,537,900	ISSUE DATE:	May 26, 2009
SERIAL NUMBER :	10/634,309	EXAMINER :	Gerald R. Ewoldt
FILING DATE :	August 4, 2003	ART UNIT :	1644
FOR :	METHOD FOR DIAGNOSING MULTIPLE SCLEROSIS		

**Certificate of Correction Branch**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 CFR § 1.322**

The patentee of the above-identified patent, through its attorney, hereby requests issuance of a Certificate of Correction. A certificate is required to correct errors, as follows:

The claims:

Column 23, line 55, claim 2, the phrase "is an anti-Glc ( $\alpha$ )<sub>13</sub>IgM type antibody, and" should read --is an anti-Glc ( $\alpha$ ) IgM type antibody, and --.

The corrections are not believed to involve such change as would constitute new matter or require examination.

It is respectfully requested that a Certificate of Correction be issued pursuant to 35 U.S.C. 254 to correct the errors in the claims. Enclosed herewith is a copy of a proposed Certificate of Correction indicating the errors and corrections thereof.

Applicant: Dotan, et al.  
Patent Number: 7,537,900

No fees are believed due in connection with this submission, however, the Commissioner is hereby authorized to charge any fees due, or credit any overpayment of same, to Deposit Account No. 50-0311; Reference No. 25681-501 UTIL.

Respectfully submitted,



---

Ingrid A. Beattie Reg. No. 42,306  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
**Customer Number 30623**

Dated: June 8, 2009

ACTIVE 4629866v.1

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

Page 1 of 1

PATENT NO. : 7,537,900  
APPLICATION NO.: 10/634,309  
ISSUE DATE : May 26, 2009  
INVENTOR(S) : Dotan, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**In the Claims:**

Column 23, line 55, claim 2, "is an anti-Glc ( $\alpha$ )<sub>13</sub>IgM type antibody, and" should read --is an anti-Glc ( $\alpha$ ) IgM type antibody, and --.

**MAILING ADDRESS OF SENDER (Please do not use customer number below):**

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC  
One Financial Center  
Boston, MA 02201

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*